| Market Cap | 23.51M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -101.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -46.00% |
| Sales | 4.16M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 61.00% |
| Dividend | N/A | Price/Book | 0.20 | EPS next 5Y | - | 52W High Chg | -70.00% |
| Recommedations | - | Quick Ratio | 3.65 | Shares Outstanding | 7.23M | 52W Low Chg | 475,900.00% |
| Insider Own | 33.98% | ROA | 0.45% | Shares Float | 5.35M | Beta | 0.20 |
| Inst Own | 2.79% | ROE | -181.08% | Shares Shorted/Prior | -/- | Price | 4.76 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 16 | Target Price | - |
| Oper. Margin | -3,487.70% | Earnings Date | Oct 2 | Volume | 6 | Change | 0.00% |
Evolva Holding SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was founded in 2004 and is headquartered in Reinach, Switzerland.
